Clinical trials: Lamivudine
HIV Infections
A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection
242 patients (121 patients in each of the two treatment arms) will be included with a confirmed diagnosis of HIV-1 infection and with a stable antiretroviral treatment during more than 48 weeks with dual therapy (DTG + 3TC)
- Trial name
- InSTINCT (NCT04076423)
- Testing
- Dual Therapy, Triple therapy
- Where
- 18 sites in Spain
- Volunteers
- 141 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV Infection
Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa
Multicenter, randomized, superiority trial to evaluate efficacy of a mono or bi-therapy of protease inhibitors with or without lamivudine over a period of 96 weeks. The primary outcome will be the failure rate at 96 weeks.
- Trial name
- MOBIDIP (NCT01905059)
- Testing
- monoPI - boosted lopinavir or boosted darunavir, bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine
- Where
- 5 sites in Burkina Faso, Cameroon and 1 more
- Volunteers
- 265 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Antiretroviral Treatment, HIV Infection
Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN
The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir…
- Conditions
- Antiretroviral Treatment, HIV Infection, Metabolic Cardiovascular Syndrome
- Trial name
- MICTLAN (NCT06629480)
- Testing
- Bictegravir
- Where
- Mexico
- Volunteers
- 378 people
- Sponsor
- Instituto Mexicano del Seguro Social
Acquired Immunodeficiency Syndrome, HIV Infections
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
This study is to evaluate the safety and tolerability of cobicistat-boosted darunavir plus two fully active nucleoside analogue reverse transcriptase inhibitors in HIV 1 infected, antiretroviral treatment-naive and…
- Trial name
- NCT01440569
- Testing
- COBI, DRV, NRTIs
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- Gilead Sciences
HIV-1-infection, Antiviral Drug Adverse Reaction
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued treatment with a non- dolutegravir…
- Conditions
- HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities
- Trial name
- NCT04340388
- Testing
- Dolutegravir 50 MG, Antiretroviral/Anti HIV
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Augusta University
Amyotrophic Lateral Sclerosis
Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).
This is a phase 2a open label, multicentre design study to investigate the safety of Triumeq in patients with ALS at 24 weeks post treatment.
- Trial name
- Lighthouse (NCT02868580)
- Testing
- Triumeq
- Where
- 4 sites in Australia
- Volunteers
- 43 people
- Sponsor
- Neuroscience Trials Australia
Acquired Immunodeficiency Syndrome
PI Vs. NNRTI Based Therapy for HIV Advanced Disease
Ritonavir boosted protease inhibitor based therapy will have equivalent antiviral efficacy over 48 weeks compared to NNRTI based therapy in patients who are antiretroviral therapy naïve and initiate therapy with CD4 counts ≤…
- Trial name
- NCT00162643
- Testing
- zidovudine+lamivudine+lopinavir/ritonavir, zidovudine + lamivudine + efavirenz
- Where
- 5 sites in Mexico
- Volunteers
- 300 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran